KAISA HEALTH (00876) announced its interim results, reporting a loss attributable to equity holders of HK$60.168 million, a year-on-year increase of approximately 6.77 times.
Kaisa Health (00876) announced its mid-term results for 2026, with revenue of approximately HKD 285 million, a year-on-year decrease of about 15.85%; the loss attributable to equity holders of the company was HKD 60.168 million, a year-on-year increase of approximately 6.77 times; the loss per share was 1.24 HK cents.
KAISA HEALTH (00876) announced its interim results for 2026, with revenue of approximately HK$285 million, a year-on-year decrease of about 15.85%; the loss attributable to equity holders of the company was HK$60.168 million, an increase of approximately 6.77 times year-on-year; the loss per share was HK$1.24.
Related Articles
SAIMO (02571) announced its interim results, reporting a loss attributable to shareholders of 48.049 million yuan, a year-on-year shift from profit to loss.
DEXIN SER GROUP (02215) announced its interim results, with a profit attributable to shareholders of 30.465 million yuan, a year-on-year decrease of 10.76%.
VEDAN INT'L (02317) will distribute an interim dividend of HKD 0.04106 per share on October 12.
SAIMO (02571) announced its interim results, reporting a loss attributable to shareholders of 48.049 million yuan, a year-on-year shift from profit to loss.
DEXIN SER GROUP (02215) announced its interim results, with a profit attributable to shareholders of 30.465 million yuan, a year-on-year decrease of 10.76%.
VEDAN INT'L (02317) will distribute an interim dividend of HKD 0.04106 per share on October 12.
RECOMMEND
